Treatment as prevention--a double hat-trick.

208 www.thelancet.com Vol 378 July 16, 2011 4 Family Health International. FHI statement on the FEM-PrEP HIV prevention study. http://minilicious.wordpress.com/2011/04/18/fh i-statement-onthe-fem-prep-hiv-prevention-study/ (accessed June 28, 2011). 5 Abdool Karim SS, Kashuba A, Werner L, Abdool Karim Q. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 2011; 378: 279–81. 6 Hendrix C, Minnis A, Guddera V, et al. MTN-001: a phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in signifi cantly diff erent product acceptability and vaginal tissue drug concentrations. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA. Feb 27–March 22, 2011. 35LB (abstr). 7 Patterson KB, Prince HA, Kraft E, et al. Exposure of extracellular and intracellular tenofovir and emtricitabine in mucosal tissues after a single of fi xed-dose TDF/FTC: implications for pre-exposure HIV prophylaxis (PrEP). XVIII International AIDS Conference; Vienna, Austria. July 18–23, 2010. THBS0305 (abstr). 8 UNAIDS. UNAIDS report on the global AIDS epidemic 2010. Geneva: joint United Nations programme on HIV/AIDS. 2010. http://www.unaids.org/ globalreport/ (accessed Feb 11, 2011). 9 Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-eff ectiveness. Clin Infect Dis 2009; 48: 806–15. 10 Walensky R, Park J-E, Wood R, et al. Cost eff ectiveness of PrEP for HIV infection in South Africa. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA. Feb 27–March 22, 2011. 37LB (abstr).